Key points from article :
ThirdLaw Molecular Inc. has unveiled a groundbreaking platform featuring a 4.5-billion molecule DNA-encoded library of Spiroligomer™ macromolecules, signalling a potential shift in therapeutic innovation. These synthetic molecules combine the selectivity of biologics with the favourable drug-like properties of small molecules, offering a promising approach to target previously “undruggable” proteins. Their design enables cell penetration, oral bioavailability, and scalable manufacturing, making them a versatile and efficient solution for drug discovery.
Spiroligomers™ stand out by overcoming limitations of traditional small molecules and biologics, offering fewer off-target effects and improved stability without complex storage needs. The library accelerates the discovery and development of new therapies through rapid screening and optimization, marking a significant milestone in creating highly selective drugs with nanomolar binding precision.
By opening its platform for collaboration with pharmaceutical partners, ThirdLaw Molecular aims to transform how diseases are diagnosed and treated. The company sees this innovation as a pivotal moment in therapeutic development, with board member J. David Owens highlighting its potential to redefine disease treatment and bring new hope to patients worldwide.
